EA200401617A1 - COMBINATION OF NMDA ANTAGONIST AND ACETYL CHOLINESTERASE INHIBITORS FOR THE TREATMENT OF ALCHEIMER'S Disease - Google Patents

COMBINATION OF NMDA ANTAGONIST AND ACETYL CHOLINESTERASE INHIBITORS FOR THE TREATMENT OF ALCHEIMER'S Disease

Info

Publication number
EA200401617A1
EA200401617A1 EA200401617A EA200401617A EA200401617A1 EA 200401617 A1 EA200401617 A1 EA 200401617A1 EA 200401617 A EA200401617 A EA 200401617A EA 200401617 A EA200401617 A EA 200401617A EA 200401617 A1 EA200401617 A1 EA 200401617A1
Authority
EA
Eurasian Patent Office
Prior art keywords
alcheimer
disease
treatment
combination
cholinesterase inhibitors
Prior art date
Application number
EA200401617A
Other languages
Russian (ru)
Other versions
EA007632B1 (en
Inventor
Ларс Ликке Томсен
Андерс Герсел Педерсен
Original Assignee
Х. Лундбекк А/С
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=28051666&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=EA200401617(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Х. Лундбекк А/С filed Critical Х. Лундбекк А/С
Priority claimed from PCT/DK2003/000342 external-priority patent/WO2003101458A1/en
Publication of EA200401617A1 publication Critical patent/EA200401617A1/en
Publication of EA007632B1 publication Critical patent/EA007632B1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/473—Quinolines; Isoquinolines ortho- or peri-condensed with carbocyclic ring systems, e.g. acridines, phenanthridines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Фармацевтическая композиция, содержащая (a) эффективное количество одного или нескольких ингибиторов ацетилхолинэстеразы или его фармацевтически эффективной соли и (b) эффективное количество одного или нескольких NMDA-антагонистов.Международная заявка была опубликована вместе с отчетом о международном поиске.A pharmaceutical composition containing (a) an effective amount of one or more acetylcholinesterase inhibitors or a pharmaceutically effective salt thereof, and (b) an effective amount of one or more NMDA antagonists. The international application was published along with an international search report.

EA200401617A 2002-05-31 2003-05-22 A combination of an nmda-antagonist and acetylchloride esterase inhibitors for the treatment of alzheimer's disease EA007632B1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US38446702P 2002-05-31 2002-05-31
DKPA200200844 2002-05-31
PCT/DK2003/000342 WO2003101458A1 (en) 2002-05-31 2003-05-22 A combination of an nmda-antagonist and acetylcholine esterase inhibitors for the treatment of alzheimer's disease

Publications (2)

Publication Number Publication Date
EA200401617A1 true EA200401617A1 (en) 2005-06-30
EA007632B1 EA007632B1 (en) 2006-12-29

Family

ID=28051666

Family Applications (1)

Application Number Title Priority Date Filing Date
EA200401617A EA007632B1 (en) 2002-05-31 2003-05-22 A combination of an nmda-antagonist and acetylchloride esterase inhibitors for the treatment of alzheimer's disease

Country Status (9)

Country Link
KR (1) KR101016927B1 (en)
CN (1) CN1655793A (en)
AR (1) AR040121A1 (en)
CA (1) CA2426492C (en)
EA (1) EA007632B1 (en)
IS (1) IS7558A (en)
PE (1) PE20040623A1 (en)
UA (1) UA82480C2 (en)
ZA (1) ZA200409147B (en)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA107653U (en) 2012-10-01 2016-06-24 Общєство С Огранічєнной Отвєтствєнностью "Валєнта-Інтєллєкт" COMPOSITION OF MEDICINAL PRODUCTS FOR TREATMENT AND PREVENTION OF BEHAVIORAL, MENTAL, AND COGNITIVE DISORDERS
CN105294450B (en) * 2014-05-29 2024-05-17 广州喜鹊医药有限公司 Amantadine nitrate compound with neuroprotection effect, preparation and medical application thereof
WO2018062941A1 (en) * 2016-09-30 2018-04-05 주식회사 바이오파마티스 Pharmaceutical composition for preventing or treating dementia and cognitive dysfunction, containing donepezil or pharmaceutically acceptable salt thereof and memantine or pharmaceutically acceptable salt thereof, and preparation method therefor
KR20210072569A (en) 2019-12-09 2021-06-17 주식회사 종근당 Complex formulation comprising donepezil and memantine

Also Published As

Publication number Publication date
PE20040623A1 (en) 2004-09-11
ZA200409147B (en) 2006-06-28
CN1655793A (en) 2005-08-17
CA2426492C (en) 2006-10-03
AR040121A1 (en) 2005-03-16
IS7558A (en) 2004-11-26
UA82480C2 (en) 2008-04-25
KR20050024296A (en) 2005-03-10
EA007632B1 (en) 2006-12-29
CA2426492A1 (en) 2003-09-16
KR101016927B1 (en) 2011-02-28

Similar Documents

Publication Publication Date Title
NO20045434L (en) A combination of an NMDA antagonist and acetylcholinesterase inhibitors for the treatment of Alzheimer's disease
BG66085B1 (en) Phenylalanine derivatives
EA200200571A1 (en) NEW COMPOSITION AND ITS APPLICATION
DE69925133D1 (en) PYRROLOBENZODIAZEPINE
CY1106697T1 (en) N-SUBSTITUTED HYDROMORPHONES AND THEIR USE
ID26984A (en) SULFONAMIDE COMPOUNDS AS DOUBLE ENDOTELINE ANGIOTENSIN RECEPTOR ANTAGONISTS
BR0308243A (en) Compound, pharmaceutical formulation, and, methods of treating diabetes, alzheimer's disease, and inhibiting gsk-3 in a mammal
ECSP055701A (en) NEW DERIVATIVES OF PYRIMIDINAMIDE AND THE USE OF THE SAME
EA200300183A1 (en) NEW COMBINATION OF THE AGONIST (5-TH2) AND THE ANTAGONIST (5-HT6) SEROTONIN AS A PHARMACEUTICAL COMPOSITION
EA200200194A1 (en) ANTAGONISTS OF THE CHEMOKINE RECEPTOR AND METHODS OF THEIR APPLICATION
EA200301223A1 (en) DOSAGE FORMS OF OXCARBAZEPINA
DE60302157D1 (en) OPIOID RECEPTOR ANTAGONISTS
EA200401227A1 (en) DELIVERY DELIVERY SYSTEM WITH CONTROLLED DELAY, INCLUDING PRAVASTATIN
EA200001039A1 (en) CALCYLYTIC COMPOUNDS
SE9802208D0 (en) Novel compounds
EE200100104A (en) A novel oral dosage form of a 5-HT4 agonist or antagonist
DK1458393T3 (en) Substituted diketopiperazines as oxytocin antagonists
EE200100520A (en) N- (2-phenyl-4-aminobutyl) -1-naphthamides as neurokinin-1 receptor antagonists
DE60134735D1 (en) NEW NEUROKININ ANTAGONISTS FOR USE AS DRUGS
EA200401137A1 (en) PHARMACEUTICAL COMPOSITION CONTAINING PDE4 INHIBITOR OR PDE3 / 4 AND ANTAGONIST OF HISTAMINE RECEPTOR
EE200300129A (en) Use of distamycin alpha-haloacryloyl derivative
DE69917005D1 (en) SUBSTITUTED PYRROLOBENZIMIDAZOLE DERIVATIVES FOR ANTI-INFLAMMATION
EA200000198A1 (en) 2-ACYLAMINOPROPANAMINES AS ANTAGONISTS OF TACHYKININ RECEPTORS
ATE330599T1 (en) USE OF ANGIOTENSIN II RECEPTOR ANTAGONISTS FOR THE TREATMENT OF ACUTE MYOCARDIC INFARCT
EA200401617A1 (en) COMBINATION OF NMDA ANTAGONIST AND ACETYL CHOLINESTERASE INHIBITORS FOR THE TREATMENT OF ALCHEIMER'S Disease

Legal Events

Date Code Title Description
MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): AM AZ KZ KG MD TJ TM

MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): BY RU